Plasmablastic lymphoma associated to Crohn's disease and hepatitis C virus chronic infection
Author(s) -
Rocío Plaza,
Ángel Ponferrada,
Dulce María Benito,
Noelia Arévalo,
María Ángeles Foncillas,
María Luisa de Fuenmayor,
Mercedes Aldeguer
Publication year - 2011
Publication title -
journal of crohn s and colitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.277
H-Index - 80
eISSN - 1876-4479
pISSN - 1873-9946
DOI - 10.1016/j.crohns.2011.07.002
Subject(s) - medicine , azathioprine , lymphoma , plasmablastic lymphoma , infliximab , disease , lymphoproliferative disorders , crohn's disease , inflammatory bowel disease , virus , immunology , gastroenterology , dermatology
Plasmablastic lymphoma is a very rare and recently-described subtype of diffuse large B-cell lymphoma. It has a poor prognosis despite intensive chemotherapy treatment. A 57-year old woman with perianal Crohn's disease receiving azathioprine and infliximab developed this type of lymphoma after a short period of time on the treatment. She also had a hepatitis C virus chronic infection which had not been diagnosed or treated before. There is no solid scientific evidence that either immunomodulators or anti-TNF drugs have a definitive role in the appearance of malignancies, and therefore there are no clear recommendations to limit their use. In these patients, there are some other factors we have to take into account, like the inflammatory bowel disease in itself and its behaviour over time, or the comorbidities of the patient, with special attention to virus infections. In this case report, we will analyse the role of these factors in the development of lymphoproliferative disorders and the recommendations given by experts to avoid their appearance.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom